RxDoctor Payments Data

Craig Chanin, MD

Family Medicine · Los Angeles, CANPI 1831222744

Payments from drug & device makers

$919in general payments, 2019–2025

Across 46 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$191
  • Amgen$153
  • GSK$145
  • Mannkind Corporation$108
  • Merck$51
  • Novo Nordisk$49
  • plus $222 from 8 others

What the payments were for

  • Food & beverage$919100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$919 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$105,803
Medicare patients
128
Services billed
788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide41$61,138
JardianceEmpagliflozin44$44,281
EliquisApixaban34$37,505
OzempicSemaglutide21$27,985
XareltoRivaroxaban14$16,142
JanuviaSitagliptin Phosphate13$15,546
FarxigaDapagliflozin Propanediol16$15,017
MyrbetriqMirabegron14$14,916
Dexlansoprazole DrDexlansoprazole21$8,813
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$7,929
Clonidine30$2,496
Methenamine Hippurate14$1,563
Gabapentin38$1,062
Levothyroxine Sodium85$1,054
Memantine Hcl11$986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$191$61,13841 claims
PfizerEliquis$40$37,50534 claims
Novo NordiskOzempic$49$27,98521 claims
MerckJanuvia$51$15,54613 claims
AstraZenecaFarxiga$37$15,01716 claims
Astellas Pharma US IncMyrbetriq$22$14,91614 claims
GSKAnoro Ellipta$145$7,92914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →